Rare Cancers Australia founder and CEO Richard Vines sat down for a discussion with BioPharmaDispatch. He challenged the early direction of the health technology assessment review and called on health minister Mark Butler to set clear expectations for the process while saying it cannot be credibly conducted behind closed doors.
Richard Vines: A better designed spreadsheet is not going to help anybody
February 22, 2023 Latest NewsBioPharmaBioPharmaDispatch Executive
Latest Video
New Stories
-
Final days to help build Australia’s longest running life sciences benchmark survey
July 15, 2025 - - Latest News -
New Australian collaboration to build gene and cell therapy production
July 15, 2025 - - Latest News -
The need to correct a profound misconception of what ethical decision-making is and is not
July 15, 2025 - - Latest News -
Patient Voice Initiative announces the appointment of new president
July 15, 2025 - - Latest News -
HTA reform is fine, but why is the underpinning framework immutable?
July 15, 2025 - - Latest News -
Olympian joins call urging vigilance on meningococcal risk
July 15, 2025 - - Latest News -
Amplia Therapeutics announces additional confirmed partial response in ACCENT trial
July 14, 2025 - - Australian Biotech